Review



rat anti mouse nkg2d monoclonal antibody  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Bio X Cell rat anti mouse nkg2d monoclonal antibody
    (A) Experimental design and protocol: AJ or AJ.Rae-1 ⁻/⁻ donor kidneys were transplanted into B6.CCR5 ⁻/⁻ recipients, B6.CCR5 ⁻/⁻ <t>NKG2D</t> ⁻/⁻ recipients, or B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb (250 µg/mouse administered on days 8, 13, 18, 23, 30, and 40 after transplantation). Nephrectomy of the native kidney was performed on day 4. (B) AJ (n=6) or AJ.Rae-1 ⁻/⁻ (n=5) kidney allografts were transplanted to groups of B6.CCR5 -/- recipients and allograft survival was monitored. All AJ.Rae-1e ⁻/⁻ kidneys survived for more than 55 days after transplantation with significantly prolonged graft survival compared with A/J kidney allografts by Kaplan–Meier analysis with log-rank test (p = 0.0018). (C) Serum from wild-type C57BL/6 or B6.CCR5 -/- recipients of A/J or AJ.Rae-1 ⁻/⁻ kidney grafts was obtained from individual recipients at the indicated times after transplant and the DSA titers. Data indicate mean DSA titer for each graft recipient group ± SD. (D) AJ kidney allografts were transplanted to groups (n = 6/group) of B6.CCR5 -/- recipients and allograft survival was monitored. Kaplan–Meier analysis with log-rank test was used to analyze graft survival in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb transplanted AJ kidney allografts. Both genetic deletion of NKG2D and antibody-mediated blockade significantly prolonged graft survival compared with B6.CCR5 ⁻/⁻ controls (p=0.0007 and p=0.0159, respectively). (E) Serum DSA titers in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb transplanted AJ kidney allografts., and AJ→B6.CCR5⁻ / ⁻ recipients at the indicated time points. Data indicate mean titer for each graft recipient group ± SD
    Rat Anti Mouse Nkg2d Monoclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 232 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+anti+mouse+nkg2d+monoclonal+antibody/InVivoMAb+anti-human+NKG2D/bio_rxiv__64898__2026__03__03__709363-103-16-25
    Average 94 stars, based on 232 article reviews
    rat anti mouse nkg2d monoclonal antibody - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand"

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand

    Journal: bioRxiv

    doi: 10.64898/2026.03.03.709363

    (A) Experimental design and protocol: AJ or AJ.Rae-1 ⁻/⁻ donor kidneys were transplanted into B6.CCR5 ⁻/⁻ recipients, B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ recipients, or B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb (250 µg/mouse administered on days 8, 13, 18, 23, 30, and 40 after transplantation). Nephrectomy of the native kidney was performed on day 4. (B) AJ (n=6) or AJ.Rae-1 ⁻/⁻ (n=5) kidney allografts were transplanted to groups of B6.CCR5 -/- recipients and allograft survival was monitored. All AJ.Rae-1e ⁻/⁻ kidneys survived for more than 55 days after transplantation with significantly prolonged graft survival compared with A/J kidney allografts by Kaplan–Meier analysis with log-rank test (p = 0.0018). (C) Serum from wild-type C57BL/6 or B6.CCR5 -/- recipients of A/J or AJ.Rae-1 ⁻/⁻ kidney grafts was obtained from individual recipients at the indicated times after transplant and the DSA titers. Data indicate mean DSA titer for each graft recipient group ± SD. (D) AJ kidney allografts were transplanted to groups (n = 6/group) of B6.CCR5 -/- recipients and allograft survival was monitored. Kaplan–Meier analysis with log-rank test was used to analyze graft survival in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb transplanted AJ kidney allografts. Both genetic deletion of NKG2D and antibody-mediated blockade significantly prolonged graft survival compared with B6.CCR5 ⁻/⁻ controls (p=0.0007 and p=0.0159, respectively). (E) Serum DSA titers in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb transplanted AJ kidney allografts., and AJ→B6.CCR5⁻ / ⁻ recipients at the indicated time points. Data indicate mean titer for each graft recipient group ± SD
    Figure Legend Snippet: (A) Experimental design and protocol: AJ or AJ.Rae-1 ⁻/⁻ donor kidneys were transplanted into B6.CCR5 ⁻/⁻ recipients, B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ recipients, or B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb (250 µg/mouse administered on days 8, 13, 18, 23, 30, and 40 after transplantation). Nephrectomy of the native kidney was performed on day 4. (B) AJ (n=6) or AJ.Rae-1 ⁻/⁻ (n=5) kidney allografts were transplanted to groups of B6.CCR5 -/- recipients and allograft survival was monitored. All AJ.Rae-1e ⁻/⁻ kidneys survived for more than 55 days after transplantation with significantly prolonged graft survival compared with A/J kidney allografts by Kaplan–Meier analysis with log-rank test (p = 0.0018). (C) Serum from wild-type C57BL/6 or B6.CCR5 -/- recipients of A/J or AJ.Rae-1 ⁻/⁻ kidney grafts was obtained from individual recipients at the indicated times after transplant and the DSA titers. Data indicate mean DSA titer for each graft recipient group ± SD. (D) AJ kidney allografts were transplanted to groups (n = 6/group) of B6.CCR5 -/- recipients and allograft survival was monitored. Kaplan–Meier analysis with log-rank test was used to analyze graft survival in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb transplanted AJ kidney allografts. Both genetic deletion of NKG2D and antibody-mediated blockade significantly prolonged graft survival compared with B6.CCR5 ⁻/⁻ controls (p=0.0007 and p=0.0159, respectively). (E) Serum DSA titers in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb transplanted AJ kidney allografts., and AJ→B6.CCR5⁻ / ⁻ recipients at the indicated time points. Data indicate mean titer for each graft recipient group ± SD

    Techniques Used: Transplantation Assay

    (A) Representative C4d immunohistochemical staining of kidney allografts at day 15 POD. Immunohistology demonstrates diffuse strong deposition of C4D in peritubular and glomerular capillaries of AJ kidney allografts to wild-type C57BL/6, B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and AJ.Rae-1 ⁻/⁻ kidney allografts to B6.CCR5 ⁻/⁻ recipients with capillary dilation observed in A/J to B6.CCR5 ⁻/⁻ recipients. (B) Periodic acid–Schiff (PAS) staining of kidney allografts reveals cortical edema and dilation of peritubular capillaries in AJ graft to B6.CCR5 ⁻/⁻ . In contrast, AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ showed attenuated tissue injury with reduced edema. Scale bars, 100 μm (low power) and 50 μm (high power). (C) Quantitative PCR analysis of NKG2D ligands (Rae-1e, Rae-1d, and H60b) in kidney grafts on day 15 POD. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Rae-1e expression was significantly reduced in AJ grafts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients compared with expression in AJ grafts to B6.CCR5⁻ / ⁻ recipients; whereas, Rae-1d and H60b expression showed no significant differences in allograft groups. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.
    Figure Legend Snippet: (A) Representative C4d immunohistochemical staining of kidney allografts at day 15 POD. Immunohistology demonstrates diffuse strong deposition of C4D in peritubular and glomerular capillaries of AJ kidney allografts to wild-type C57BL/6, B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and AJ.Rae-1 ⁻/⁻ kidney allografts to B6.CCR5 ⁻/⁻ recipients with capillary dilation observed in A/J to B6.CCR5 ⁻/⁻ recipients. (B) Periodic acid–Schiff (PAS) staining of kidney allografts reveals cortical edema and dilation of peritubular capillaries in AJ graft to B6.CCR5 ⁻/⁻ . In contrast, AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ showed attenuated tissue injury with reduced edema. Scale bars, 100 μm (low power) and 50 μm (high power). (C) Quantitative PCR analysis of NKG2D ligands (Rae-1e, Rae-1d, and H60b) in kidney grafts on day 15 POD. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Rae-1e expression was significantly reduced in AJ grafts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients compared with expression in AJ grafts to B6.CCR5⁻ / ⁻ recipients; whereas, Rae-1d and H60b expression showed no significant differences in allograft groups. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.

    Techniques Used: Immunohistochemical staining, Staining, Real-time Polymerase Chain Reaction, Expressing, Comparison

    Quantitative PCR analysis of transcripts encoding mediators associated with antibody-mediated rejection (ABMR) was performed in kidney grafts harvested on day 15 POD. The expression levels of IFN-γ, Gzmb (GZB), Perforin, TNFα, CCL2, CXCL9, CXCL10, CX3CR1, MyBL1, and SH2D1B1 were compared between B6 isografts to B6 recipients, AJ allografts to B6.CCR5 ⁻/⁻ , A/J allografts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA with appropriate post hoc comparisons. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.
    Figure Legend Snippet: Quantitative PCR analysis of transcripts encoding mediators associated with antibody-mediated rejection (ABMR) was performed in kidney grafts harvested on day 15 POD. The expression levels of IFN-γ, Gzmb (GZB), Perforin, TNFα, CCL2, CXCL9, CXCL10, CX3CR1, MyBL1, and SH2D1B1 were compared between B6 isografts to B6 recipients, AJ allografts to B6.CCR5 ⁻/⁻ , A/J allografts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA with appropriate post hoc comparisons. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.

    Techniques Used: Real-time Polymerase Chain Reaction, Expressing, Comparison

    AJ kidney allografts were transplanted to groups (n = 5/group) of B6.CCR5 -/- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and in AJ.Rae-1 ⁻/⁻ allografts transplanted to B6.CCR5 ⁻/⁻ recipients. (A) Representative flow cytometric analysis of infiltrating NK cells in kidney allografts on day 15 post-transplant. Single-cell suspensions were prepared from graft tissues and gated on CD45⁺ leukocytes, followed by exclusion of CD3⁺ cells. NK cells were defined as NK1.1⁺DX5⁺ cells within the CD45⁺CD3⁻ population. (B) Quantification of total NK cell numbers per mg of graft tissue in the indicated groups. Absence of recipient NKG2D or donor Rae-1 suppresses NK cell accumulation. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of BrdU incorporation in graft-infiltrating NK cells. BrdU was administered i.p. on POD 14 and allografts were harvested and cell aliquots stained to detect BrdU + NK1.1 + cells (D) Quantification of BrdU⁺ NK cell numbers per mg of graft tissue. NKG2D deficiency or blockade and absence of donor Rae-1 decreased NK cell proliferation within the graft. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test. (E) ELISA analysis of cytokine levels in graft tissues on day 15 post-transplant. IL-21 levels were increased in AJ grafts to B6.CCR5 ⁻/⁻ recipients compared with the other groups, whereas IL-15 and IL-7 levels showed no significant differences among groups. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.
    Figure Legend Snippet: AJ kidney allografts were transplanted to groups (n = 5/group) of B6.CCR5 -/- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and in AJ.Rae-1 ⁻/⁻ allografts transplanted to B6.CCR5 ⁻/⁻ recipients. (A) Representative flow cytometric analysis of infiltrating NK cells in kidney allografts on day 15 post-transplant. Single-cell suspensions were prepared from graft tissues and gated on CD45⁺ leukocytes, followed by exclusion of CD3⁺ cells. NK cells were defined as NK1.1⁺DX5⁺ cells within the CD45⁺CD3⁻ population. (B) Quantification of total NK cell numbers per mg of graft tissue in the indicated groups. Absence of recipient NKG2D or donor Rae-1 suppresses NK cell accumulation. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of BrdU incorporation in graft-infiltrating NK cells. BrdU was administered i.p. on POD 14 and allografts were harvested and cell aliquots stained to detect BrdU + NK1.1 + cells (D) Quantification of BrdU⁺ NK cell numbers per mg of graft tissue. NKG2D deficiency or blockade and absence of donor Rae-1 decreased NK cell proliferation within the graft. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test. (E) ELISA analysis of cytokine levels in graft tissues on day 15 post-transplant. IL-21 levels were increased in AJ grafts to B6.CCR5 ⁻/⁻ recipients compared with the other groups, whereas IL-15 and IL-7 levels showed no significant differences among groups. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.

    Techniques Used: Single Cell, BrdU Incorporation Assay, Staining, Enzyme-linked Immunosorbent Assay

    (A) Representative histograms of CD107a + NK cells in kidney allografts. CD107a expression was assessed within graft-infiltrating NK cells defined as CD45⁺CD3⁻ NK1.1⁺DX5⁺ cells among the groups of AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. (B) Quantification of CD107a⁺ NK cell numbers per mg of graft tissue in the groups. NKG2D deficiency or blockade and absence of donor Rae-1 reduced the number of CD107a⁺ NK cell compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of NKG2D expression within graft-infiltrating NK cells (CD45⁺CD3⁻NK1.1⁺DX5⁺) and (D) CD107a + NK cell subset in the indicated groups. The expression of NKG2D was reduced in recipient NKG2D-deficient or donor Rae-1-deficient conditions.
    Figure Legend Snippet: (A) Representative histograms of CD107a + NK cells in kidney allografts. CD107a expression was assessed within graft-infiltrating NK cells defined as CD45⁺CD3⁻ NK1.1⁺DX5⁺ cells among the groups of AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. (B) Quantification of CD107a⁺ NK cell numbers per mg of graft tissue in the groups. NKG2D deficiency or blockade and absence of donor Rae-1 reduced the number of CD107a⁺ NK cell compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of NKG2D expression within graft-infiltrating NK cells (CD45⁺CD3⁻NK1.1⁺DX5⁺) and (D) CD107a + NK cell subset in the indicated groups. The expression of NKG2D was reduced in recipient NKG2D-deficient or donor Rae-1-deficient conditions.

    Techniques Used: Expressing

    (A) Representative flow cytometric analysis of graft-infiltrating Ly6C hi CD11b hi monocytes. After exclusion of dead cells, leukocytes were gated as CD45⁺ cells, followed by exclusion of CD3⁺ cells. CD11b⁺Ly6G⁻ cells were identified, and F4/80⁻ cells were defined as monocytes. Ly6C expression was evaluated within this monocyte population. Representative contour plots were obtained from AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Quantification of Ly6C⁺ monocyte numbers per mg of graft tissue and Mean fluorescence intensity (MFI) of Ly6C expression in graft-infiltrating monocytes were evaluated in the indicated groups. Rae-1 deficiency grafts reduced MFI of Ly6C expression in monocytes compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.
    Figure Legend Snippet: (A) Representative flow cytometric analysis of graft-infiltrating Ly6C hi CD11b hi monocytes. After exclusion of dead cells, leukocytes were gated as CD45⁺ cells, followed by exclusion of CD3⁺ cells. CD11b⁺Ly6G⁻ cells were identified, and F4/80⁻ cells were defined as monocytes. Ly6C expression was evaluated within this monocyte population. Representative contour plots were obtained from AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Quantification of Ly6C⁺ monocyte numbers per mg of graft tissue and Mean fluorescence intensity (MFI) of Ly6C expression in graft-infiltrating monocytes were evaluated in the indicated groups. Rae-1 deficiency grafts reduced MFI of Ly6C expression in monocytes compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.

    Techniques Used: Expressing, Fluorescence

    Related Articles

    Transplantation Assay:

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand
    Article Snippet: .. In some experiments, B6.CCR5 -/- recipients of A/J kidney allografts were treated i.p. with 250 μg rat anti-mouse NKG2D monoclonal antibody (catalog BE0351, clone HMG2D, Bio X Cell, NH) on days 8, 13, 18, 23, 30 and 40 after transplantation. ..



    Similar Products

    94
    Bio X Cell rat anti mouse nkg2d monoclonal antibody
    (A) Experimental design and protocol: AJ or AJ.Rae-1 ⁻/⁻ donor kidneys were transplanted into B6.CCR5 ⁻/⁻ recipients, B6.CCR5 ⁻/⁻ <t>NKG2D</t> ⁻/⁻ recipients, or B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb (250 µg/mouse administered on days 8, 13, 18, 23, 30, and 40 after transplantation). Nephrectomy of the native kidney was performed on day 4. (B) AJ (n=6) or AJ.Rae-1 ⁻/⁻ (n=5) kidney allografts were transplanted to groups of B6.CCR5 -/- recipients and allograft survival was monitored. All AJ.Rae-1e ⁻/⁻ kidneys survived for more than 55 days after transplantation with significantly prolonged graft survival compared with A/J kidney allografts by Kaplan–Meier analysis with log-rank test (p = 0.0018). (C) Serum from wild-type C57BL/6 or B6.CCR5 -/- recipients of A/J or AJ.Rae-1 ⁻/⁻ kidney grafts was obtained from individual recipients at the indicated times after transplant and the DSA titers. Data indicate mean DSA titer for each graft recipient group ± SD. (D) AJ kidney allografts were transplanted to groups (n = 6/group) of B6.CCR5 -/- recipients and allograft survival was monitored. Kaplan–Meier analysis with log-rank test was used to analyze graft survival in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb transplanted AJ kidney allografts. Both genetic deletion of NKG2D and antibody-mediated blockade significantly prolonged graft survival compared with B6.CCR5 ⁻/⁻ controls (p=0.0007 and p=0.0159, respectively). (E) Serum DSA titers in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb transplanted AJ kidney allografts., and AJ→B6.CCR5⁻ / ⁻ recipients at the indicated time points. Data indicate mean titer for each graft recipient group ± SD
    Rat Anti Mouse Nkg2d Monoclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+anti+mouse+nkg2d+monoclonal+antibody/InVivoMAb+anti-human+NKG2D/bio_rxiv__64898__2026__03__03__709363-103-16-25
    Average 94 stars, based on 1 article reviews
    rat anti mouse nkg2d monoclonal antibody - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    Bio X Cell rat monoclonal nkg2d cx5

    Rat Monoclonal Nkg2d Cx5, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+anti+mouse+nkg2d+monoclonal+antibody/InVivoMAb+anti-mouse+NKG2D/pmc12032931-52-0-5
    Average 93 stars, based on 1 article reviews
    rat monoclonal nkg2d cx5 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    90
    R&D Systems monoclonal anti-mouse rae-1 ab that blocks the binding of mouse nkg2d to β and δ isoforms of mouse rae-1 (clone 199205, rat igg2b) ( 51 )

    Monoclonal Anti Mouse Rae 1 Ab That Blocks The Binding Of Mouse Nkg2d To β And δ Isoforms Of Mouse Rae 1 (Clone 199205, Rat Igg2b) ( 51 ), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+anti+mouse+nkg2d+monoclonal+antibody/anti+nkg2d/pmc03094956-71-14-29
    Average 90 stars, based on 1 article reviews
    monoclonal anti-mouse rae-1 ab that blocks the binding of mouse nkg2d to β and δ isoforms of mouse rae-1 (clone 199205, rat igg2b) ( 51 ) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher rat anti-mouse nkg2d monoclonal antibody cx5

    Rat Anti Mouse Nkg2d Monoclonal Antibody Cx5, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+anti+mouse+nkg2d+monoclonal+antibody/anti+nkg2d/10__1172_slash_jci34462-309-10-16
    Average 90 stars, based on 1 article reviews
    rat anti-mouse nkg2d monoclonal antibody cx5 - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    93
    R&D Systems rat anti mouse nkg2d monoclonal antibody

    Rat Anti Mouse Nkg2d Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+anti+mouse+nkg2d+monoclonal+antibody/Mouse+NKG2D%2FCD314+Biotinylated+Antibody/pmc01850619-213-45-50
    Average 93 stars, based on 1 article reviews
    rat anti mouse nkg2d monoclonal antibody - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    86
    Thermo Fisher rat anti mouse nkg2d monoclonal antibody cx5
    <t>NKG2D</t> ligands are induced in the lungs of mice infected with P. aeruginosa. (A) Western blot analysis of RAE-1 in whole lungs of mice exposed to ∼1 × 106 CFU of P. aeruginosa for 0, 8, and 24 h. The blot is representative of results obtained with four to six mice per group. (B to E) NKG2D ligand expression in lung epithelial cells and alveolar macrophages of mice exposed to ∼1 × 106 CFU of P. aeruginosa for 24 h. The accumulation of NKG2D ligands in the lungs of CF1 mice was assessed by immunohistochemistry analysis using paraffin-embedded sections and a goat polyclonal antibody against RAE-1γ. (B) Large airway of PBS-treated mouse. (C) Large airway of P. aeruginosa-infected mouse. (D) Lung parenchyma of PBS-treated mouse. (E) Lung parenchyma of P. aeruginosa-infected mouse. The photomicrographs are representative of five mice per group. Original magnification, ×400.
    Rat Anti Mouse Nkg2d Monoclonal Antibody Cx5, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+anti+mouse+nkg2d+monoclonal+antibody/pmc01459711-81-16-22
    Average 86 stars, based on 1 article reviews
    rat anti mouse nkg2d monoclonal antibody cx5 - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    Image Search Results


    (A) Experimental design and protocol: AJ or AJ.Rae-1 ⁻/⁻ donor kidneys were transplanted into B6.CCR5 ⁻/⁻ recipients, B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ recipients, or B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb (250 µg/mouse administered on days 8, 13, 18, 23, 30, and 40 after transplantation). Nephrectomy of the native kidney was performed on day 4. (B) AJ (n=6) or AJ.Rae-1 ⁻/⁻ (n=5) kidney allografts were transplanted to groups of B6.CCR5 -/- recipients and allograft survival was monitored. All AJ.Rae-1e ⁻/⁻ kidneys survived for more than 55 days after transplantation with significantly prolonged graft survival compared with A/J kidney allografts by Kaplan–Meier analysis with log-rank test (p = 0.0018). (C) Serum from wild-type C57BL/6 or B6.CCR5 -/- recipients of A/J or AJ.Rae-1 ⁻/⁻ kidney grafts was obtained from individual recipients at the indicated times after transplant and the DSA titers. Data indicate mean DSA titer for each graft recipient group ± SD. (D) AJ kidney allografts were transplanted to groups (n = 6/group) of B6.CCR5 -/- recipients and allograft survival was monitored. Kaplan–Meier analysis with log-rank test was used to analyze graft survival in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb transplanted AJ kidney allografts. Both genetic deletion of NKG2D and antibody-mediated blockade significantly prolonged graft survival compared with B6.CCR5 ⁻/⁻ controls (p=0.0007 and p=0.0159, respectively). (E) Serum DSA titers in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb transplanted AJ kidney allografts., and AJ→B6.CCR5⁻ / ⁻ recipients at the indicated time points. Data indicate mean titer for each graft recipient group ± SD

    Journal: bioRxiv

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand

    doi: 10.64898/2026.03.03.709363

    Figure Lengend Snippet: (A) Experimental design and protocol: AJ or AJ.Rae-1 ⁻/⁻ donor kidneys were transplanted into B6.CCR5 ⁻/⁻ recipients, B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ recipients, or B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb (250 µg/mouse administered on days 8, 13, 18, 23, 30, and 40 after transplantation). Nephrectomy of the native kidney was performed on day 4. (B) AJ (n=6) or AJ.Rae-1 ⁻/⁻ (n=5) kidney allografts were transplanted to groups of B6.CCR5 -/- recipients and allograft survival was monitored. All AJ.Rae-1e ⁻/⁻ kidneys survived for more than 55 days after transplantation with significantly prolonged graft survival compared with A/J kidney allografts by Kaplan–Meier analysis with log-rank test (p = 0.0018). (C) Serum from wild-type C57BL/6 or B6.CCR5 -/- recipients of A/J or AJ.Rae-1 ⁻/⁻ kidney grafts was obtained from individual recipients at the indicated times after transplant and the DSA titers. Data indicate mean DSA titer for each graft recipient group ± SD. (D) AJ kidney allografts were transplanted to groups (n = 6/group) of B6.CCR5 -/- recipients and allograft survival was monitored. Kaplan–Meier analysis with log-rank test was used to analyze graft survival in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and B6.CCR5 ⁻/⁻ recipients treated with anti-NKG2D mAb transplanted AJ kidney allografts. Both genetic deletion of NKG2D and antibody-mediated blockade significantly prolonged graft survival compared with B6.CCR5 ⁻/⁻ controls (p=0.0007 and p=0.0159, respectively). (E) Serum DSA titers in B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb transplanted AJ kidney allografts., and AJ→B6.CCR5⁻ / ⁻ recipients at the indicated time points. Data indicate mean titer for each graft recipient group ± SD

    Article Snippet: In some experiments, B6.CCR5 -/- recipients of A/J kidney allografts were treated i.p. with 250 μg rat anti-mouse NKG2D monoclonal antibody (catalog BE0351, clone HMG2D, Bio X Cell, NH) on days 8, 13, 18, 23, 30 and 40 after transplantation.

    Techniques: Transplantation Assay

    (A) Representative C4d immunohistochemical staining of kidney allografts at day 15 POD. Immunohistology demonstrates diffuse strong deposition of C4D in peritubular and glomerular capillaries of AJ kidney allografts to wild-type C57BL/6, B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and AJ.Rae-1 ⁻/⁻ kidney allografts to B6.CCR5 ⁻/⁻ recipients with capillary dilation observed in A/J to B6.CCR5 ⁻/⁻ recipients. (B) Periodic acid–Schiff (PAS) staining of kidney allografts reveals cortical edema and dilation of peritubular capillaries in AJ graft to B6.CCR5 ⁻/⁻ . In contrast, AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ showed attenuated tissue injury with reduced edema. Scale bars, 100 μm (low power) and 50 μm (high power). (C) Quantitative PCR analysis of NKG2D ligands (Rae-1e, Rae-1d, and H60b) in kidney grafts on day 15 POD. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Rae-1e expression was significantly reduced in AJ grafts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients compared with expression in AJ grafts to B6.CCR5⁻ / ⁻ recipients; whereas, Rae-1d and H60b expression showed no significant differences in allograft groups. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.

    Journal: bioRxiv

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand

    doi: 10.64898/2026.03.03.709363

    Figure Lengend Snippet: (A) Representative C4d immunohistochemical staining of kidney allografts at day 15 POD. Immunohistology demonstrates diffuse strong deposition of C4D in peritubular and glomerular capillaries of AJ kidney allografts to wild-type C57BL/6, B6.CCR5 ⁻/⁻ , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and AJ.Rae-1 ⁻/⁻ kidney allografts to B6.CCR5 ⁻/⁻ recipients with capillary dilation observed in A/J to B6.CCR5 ⁻/⁻ recipients. (B) Periodic acid–Schiff (PAS) staining of kidney allografts reveals cortical edema and dilation of peritubular capillaries in AJ graft to B6.CCR5 ⁻/⁻ . In contrast, AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ showed attenuated tissue injury with reduced edema. Scale bars, 100 μm (low power) and 50 μm (high power). (C) Quantitative PCR analysis of NKG2D ligands (Rae-1e, Rae-1d, and H60b) in kidney grafts on day 15 POD. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Rae-1e expression was significantly reduced in AJ grafts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ and B6.CCR5⁻ / ⁻ treated with anti-NKG2D mAb and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients compared with expression in AJ grafts to B6.CCR5⁻ / ⁻ recipients; whereas, Rae-1d and H60b expression showed no significant differences in allograft groups. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.

    Article Snippet: In some experiments, B6.CCR5 -/- recipients of A/J kidney allografts were treated i.p. with 250 μg rat anti-mouse NKG2D monoclonal antibody (catalog BE0351, clone HMG2D, Bio X Cell, NH) on days 8, 13, 18, 23, 30 and 40 after transplantation.

    Techniques: Immunohistochemical staining, Staining, Real-time Polymerase Chain Reaction, Expressing, Comparison

    Quantitative PCR analysis of transcripts encoding mediators associated with antibody-mediated rejection (ABMR) was performed in kidney grafts harvested on day 15 POD. The expression levels of IFN-γ, Gzmb (GZB), Perforin, TNFα, CCL2, CXCL9, CXCL10, CX3CR1, MyBL1, and SH2D1B1 were compared between B6 isografts to B6 recipients, AJ allografts to B6.CCR5 ⁻/⁻ , A/J allografts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA with appropriate post hoc comparisons. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.

    Journal: bioRxiv

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand

    doi: 10.64898/2026.03.03.709363

    Figure Lengend Snippet: Quantitative PCR analysis of transcripts encoding mediators associated with antibody-mediated rejection (ABMR) was performed in kidney grafts harvested on day 15 POD. The expression levels of IFN-γ, Gzmb (GZB), Perforin, TNFα, CCL2, CXCL9, CXCL10, CX3CR1, MyBL1, and SH2D1B1 were compared between B6 isografts to B6 recipients, AJ allografts to B6.CCR5 ⁻/⁻ , A/J allografts to B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Relative mRNA expression levels in each group are shown in comparison with a B6 graft to B6 recipient. Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA with appropriate post hoc comparisons. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.

    Article Snippet: In some experiments, B6.CCR5 -/- recipients of A/J kidney allografts were treated i.p. with 250 μg rat anti-mouse NKG2D monoclonal antibody (catalog BE0351, clone HMG2D, Bio X Cell, NH) on days 8, 13, 18, 23, 30 and 40 after transplantation.

    Techniques: Real-time Polymerase Chain Reaction, Expressing, Comparison

    AJ kidney allografts were transplanted to groups (n = 5/group) of B6.CCR5 -/- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and in AJ.Rae-1 ⁻/⁻ allografts transplanted to B6.CCR5 ⁻/⁻ recipients. (A) Representative flow cytometric analysis of infiltrating NK cells in kidney allografts on day 15 post-transplant. Single-cell suspensions were prepared from graft tissues and gated on CD45⁺ leukocytes, followed by exclusion of CD3⁺ cells. NK cells were defined as NK1.1⁺DX5⁺ cells within the CD45⁺CD3⁻ population. (B) Quantification of total NK cell numbers per mg of graft tissue in the indicated groups. Absence of recipient NKG2D or donor Rae-1 suppresses NK cell accumulation. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of BrdU incorporation in graft-infiltrating NK cells. BrdU was administered i.p. on POD 14 and allografts were harvested and cell aliquots stained to detect BrdU + NK1.1 + cells (D) Quantification of BrdU⁺ NK cell numbers per mg of graft tissue. NKG2D deficiency or blockade and absence of donor Rae-1 decreased NK cell proliferation within the graft. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test. (E) ELISA analysis of cytokine levels in graft tissues on day 15 post-transplant. IL-21 levels were increased in AJ grafts to B6.CCR5 ⁻/⁻ recipients compared with the other groups, whereas IL-15 and IL-7 levels showed no significant differences among groups. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.

    Journal: bioRxiv

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand

    doi: 10.64898/2026.03.03.709363

    Figure Lengend Snippet: AJ kidney allografts were transplanted to groups (n = 5/group) of B6.CCR5 -/- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and in AJ.Rae-1 ⁻/⁻ allografts transplanted to B6.CCR5 ⁻/⁻ recipients. (A) Representative flow cytometric analysis of infiltrating NK cells in kidney allografts on day 15 post-transplant. Single-cell suspensions were prepared from graft tissues and gated on CD45⁺ leukocytes, followed by exclusion of CD3⁺ cells. NK cells were defined as NK1.1⁺DX5⁺ cells within the CD45⁺CD3⁻ population. (B) Quantification of total NK cell numbers per mg of graft tissue in the indicated groups. Absence of recipient NKG2D or donor Rae-1 suppresses NK cell accumulation. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of BrdU incorporation in graft-infiltrating NK cells. BrdU was administered i.p. on POD 14 and allografts were harvested and cell aliquots stained to detect BrdU + NK1.1 + cells (D) Quantification of BrdU⁺ NK cell numbers per mg of graft tissue. NKG2D deficiency or blockade and absence of donor Rae-1 decreased NK cell proliferation within the graft. Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test. (E) ELISA analysis of cytokine levels in graft tissues on day 15 post-transplant. IL-21 levels were increased in AJ grafts to B6.CCR5 ⁻/⁻ recipients compared with the other groups, whereas IL-15 and IL-7 levels showed no significant differences among groups. Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test.

    Article Snippet: In some experiments, B6.CCR5 -/- recipients of A/J kidney allografts were treated i.p. with 250 μg rat anti-mouse NKG2D monoclonal antibody (catalog BE0351, clone HMG2D, Bio X Cell, NH) on days 8, 13, 18, 23, 30 and 40 after transplantation.

    Techniques: Single Cell, BrdU Incorporation Assay, Staining, Enzyme-linked Immunosorbent Assay

    (A) Representative histograms of CD107a + NK cells in kidney allografts. CD107a expression was assessed within graft-infiltrating NK cells defined as CD45⁺CD3⁻ NK1.1⁺DX5⁺ cells among the groups of AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. (B) Quantification of CD107a⁺ NK cell numbers per mg of graft tissue in the groups. NKG2D deficiency or blockade and absence of donor Rae-1 reduced the number of CD107a⁺ NK cell compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of NKG2D expression within graft-infiltrating NK cells (CD45⁺CD3⁻NK1.1⁺DX5⁺) and (D) CD107a + NK cell subset in the indicated groups. The expression of NKG2D was reduced in recipient NKG2D-deficient or donor Rae-1-deficient conditions.

    Journal: bioRxiv

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand

    doi: 10.64898/2026.03.03.709363

    Figure Lengend Snippet: (A) Representative histograms of CD107a + NK cells in kidney allografts. CD107a expression was assessed within graft-infiltrating NK cells defined as CD45⁺CD3⁻ NK1.1⁺DX5⁺ cells among the groups of AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. (B) Quantification of CD107a⁺ NK cell numbers per mg of graft tissue in the groups. NKG2D deficiency or blockade and absence of donor Rae-1 reduced the number of CD107a⁺ NK cell compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05, **P < 0.01 as determined by one-way ANOVA test. (C) Representative flow cytometric analysis of NKG2D expression within graft-infiltrating NK cells (CD45⁺CD3⁻NK1.1⁺DX5⁺) and (D) CD107a + NK cell subset in the indicated groups. The expression of NKG2D was reduced in recipient NKG2D-deficient or donor Rae-1-deficient conditions.

    Article Snippet: In some experiments, B6.CCR5 -/- recipients of A/J kidney allografts were treated i.p. with 250 μg rat anti-mouse NKG2D monoclonal antibody (catalog BE0351, clone HMG2D, Bio X Cell, NH) on days 8, 13, 18, 23, 30 and 40 after transplantation.

    Techniques: Expressing

    (A) Representative flow cytometric analysis of graft-infiltrating Ly6C hi CD11b hi monocytes. After exclusion of dead cells, leukocytes were gated as CD45⁺ cells, followed by exclusion of CD3⁺ cells. CD11b⁺Ly6G⁻ cells were identified, and F4/80⁻ cells were defined as monocytes. Ly6C expression was evaluated within this monocyte population. Representative contour plots were obtained from AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Quantification of Ly6C⁺ monocyte numbers per mg of graft tissue and Mean fluorescence intensity (MFI) of Ly6C expression in graft-infiltrating monocytes were evaluated in the indicated groups. Rae-1 deficiency grafts reduced MFI of Ly6C expression in monocytes compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.

    Journal: bioRxiv

    Article Title: NK Cells Effectively Mediating Antibody-Mediated Kidney Allograft Rejection Requires a Specific Activation Receptor and Graft Expression of the Ligand

    doi: 10.64898/2026.03.03.709363

    Figure Lengend Snippet: (A) Representative flow cytometric analysis of graft-infiltrating Ly6C hi CD11b hi monocytes. After exclusion of dead cells, leukocytes were gated as CD45⁺ cells, followed by exclusion of CD3⁺ cells. CD11b⁺Ly6G⁻ cells were identified, and F4/80⁻ cells were defined as monocytes. Ly6C expression was evaluated within this monocyte population. Representative contour plots were obtained from AJ grafts to B6.CCR5 /- , B6.CCR5 ⁻/⁻ NKG2D ⁻/⁻ , B6.CCR5 ⁻/⁻ treated with anti-NKG2D mAb recipients and AJ.Rae-1 ⁻/⁻ grafts to B6.CCR5 ⁻/⁻ recipients. Quantification of Ly6C⁺ monocyte numbers per mg of graft tissue and Mean fluorescence intensity (MFI) of Ly6C expression in graft-infiltrating monocytes were evaluated in the indicated groups. Rae-1 deficiency grafts reduced MFI of Ly6C expression in monocytes compared with AJ grafts to B6.CCR5 ⁻/⁻ . Data indicate the mean ± SD. *P < 0.05 as determined by one-way ANOVA test.

    Article Snippet: In some experiments, B6.CCR5 -/- recipients of A/J kidney allografts were treated i.p. with 250 μg rat anti-mouse NKG2D monoclonal antibody (catalog BE0351, clone HMG2D, Bio X Cell, NH) on days 8, 13, 18, 23, 30 and 40 after transplantation.

    Techniques: Expressing, Fluorescence

    Journal: iScience

    Article Title: Hepatic iNKT cells facilitate colorectal cancer metastasis by inducing a fibrotic niche in the liver

    doi: 10.1016/j.isci.2025.112364

    Figure Lengend Snippet:

    Article Snippet: Rat Monoclonal NKG2D (CX5) , BioXCell , BE0334; RRID: AB_2894754.

    Techniques: Recombinant, Membrane, Infection, Transfection, Plasmid Preparation, Microscopy, In Vivo, SYBR Green Assay, Amplification, Multiplexing, Staining, Reverse Transcription, RNA Sequencing, Software, Injection, Control, Ointment, Imaging

    NKG2D ligands are induced in the lungs of mice infected with P. aeruginosa. (A) Western blot analysis of RAE-1 in whole lungs of mice exposed to ∼1 × 106 CFU of P. aeruginosa for 0, 8, and 24 h. The blot is representative of results obtained with four to six mice per group. (B to E) NKG2D ligand expression in lung epithelial cells and alveolar macrophages of mice exposed to ∼1 × 106 CFU of P. aeruginosa for 24 h. The accumulation of NKG2D ligands in the lungs of CF1 mice was assessed by immunohistochemistry analysis using paraffin-embedded sections and a goat polyclonal antibody against RAE-1γ. (B) Large airway of PBS-treated mouse. (C) Large airway of P. aeruginosa-infected mouse. (D) Lung parenchyma of PBS-treated mouse. (E) Lung parenchyma of P. aeruginosa-infected mouse. The photomicrographs are representative of five mice per group. Original magnification, ×400.

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: NKG2D ligands are induced in the lungs of mice infected with P. aeruginosa. (A) Western blot analysis of RAE-1 in whole lungs of mice exposed to ∼1 × 106 CFU of P. aeruginosa for 0, 8, and 24 h. The blot is representative of results obtained with four to six mice per group. (B to E) NKG2D ligand expression in lung epithelial cells and alveolar macrophages of mice exposed to ∼1 × 106 CFU of P. aeruginosa for 24 h. The accumulation of NKG2D ligands in the lungs of CF1 mice was assessed by immunohistochemistry analysis using paraffin-embedded sections and a goat polyclonal antibody against RAE-1γ. (B) Large airway of PBS-treated mouse. (C) Large airway of P. aeruginosa-infected mouse. (D) Lung parenchyma of PBS-treated mouse. (E) Lung parenchyma of P. aeruginosa-infected mouse. The photomicrographs are representative of five mice per group. Original magnification, ×400.

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Infection, Western Blot, Expressing, Immunohistochemistry

    Expression and induction of an NKG2D ligand on the surface of human airway epithelial cells. A simian virus 40-transformed primary tracheal epithelial cell line (9HTEo-) was treated with P. aeruginosa (multiplicity of infection, 10) for 24 h. The dashed line histograms indicate the results for isotype controls, the solid line histograms indicate the results for PBS-treated cells, and the shaded histograms indicate the results for P. aeruginosa-infected cells. ULBP2 cell surface expression was assessed by immunofluorescence and fluorescence-activated cell sorting analysis using mouse monoclonal antibodies, followed by phycoerythrin-conjugated goat anti-mouse antibodies. The histograms are representative of three independent experiments.

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: Expression and induction of an NKG2D ligand on the surface of human airway epithelial cells. A simian virus 40-transformed primary tracheal epithelial cell line (9HTEo-) was treated with P. aeruginosa (multiplicity of infection, 10) for 24 h. The dashed line histograms indicate the results for isotype controls, the solid line histograms indicate the results for PBS-treated cells, and the shaded histograms indicate the results for P. aeruginosa-infected cells. ULBP2 cell surface expression was assessed by immunofluorescence and fluorescence-activated cell sorting analysis using mouse monoclonal antibodies, followed by phycoerythrin-conjugated goat anti-mouse antibodies. The histograms are representative of three independent experiments.

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Expressing, Transformation Assay, Infection, Immunofluorescence, Fluorescence, FACS

    NKG2D receptor expression on pulmonary lymphocytes. NKG2D-expressing lymphocyte populations in perfused, digested lungs were analyzed by flow cytometry. Cells were purified as described in Materials and Methods and were labeled with the following antibodies: phycoerythrin-conjugated isotype control (A), phycoerythrin-conjugated NKG2D (B), allophycocyanin-conjugated NK1.1 and phycoerythrin-conjugated NKG2D (C), and phycoerythrin-conjugated NKG2D with allophycocyanin-conjugated CD8 antibodies (D). Dot plot diagrams were derived from the lymphocyte gate ascertained from forward and side scatter plots. The dot plots are representative of three independent experiments. APC, allophycocyanin; PE, phycoerythrin.

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: NKG2D receptor expression on pulmonary lymphocytes. NKG2D-expressing lymphocyte populations in perfused, digested lungs were analyzed by flow cytometry. Cells were purified as described in Materials and Methods and were labeled with the following antibodies: phycoerythrin-conjugated isotype control (A), phycoerythrin-conjugated NKG2D (B), allophycocyanin-conjugated NK1.1 and phycoerythrin-conjugated NKG2D (C), and phycoerythrin-conjugated NKG2D with allophycocyanin-conjugated CD8 antibodies (D). Dot plot diagrams were derived from the lymphocyte gate ascertained from forward and side scatter plots. The dot plots are representative of three independent experiments. APC, allophycocyanin; PE, phycoerythrin.

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Expressing, Flow Cytometry, Purification, Labeling, Derivative Assay

    NKG2D signaling blockade inhibits the pulmonary clearance of P. aeruginosa. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and the bacterial CFU in the lungs were assessed at 24 h. Larger amounts of P. aeruginosa were recovered from the lungs of mice that were treated with the CX5 antibody. The data are means and standard errors of the means for seven or eight mice per group. The asterisk indicates that the value was significantly greater than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: NKG2D signaling blockade inhibits the pulmonary clearance of P. aeruginosa. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and the bacterial CFU in the lungs were assessed at 24 h. Larger amounts of P. aeruginosa were recovered from the lungs of mice that were treated with the CX5 antibody. The data are means and standard errors of the means for seven or eight mice per group. The asterisk indicates that the value was significantly greater than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Blocking Assay, Infection

    NKG2D signaling blockade does not impair AM phagocytosis of P. aeruginosa. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to GFP-PAO1 infection, and the percentages of AM in the bronchoalveolar lavage that had ingested bacteria were determined by fluorescence microscopy. The data are means and standard errors of the means for three mice per group.

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: NKG2D signaling blockade does not impair AM phagocytosis of P. aeruginosa. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to GFP-PAO1 infection, and the percentages of AM in the bronchoalveolar lavage that had ingested bacteria were determined by fluorescence microscopy. The data are means and standard errors of the means for three mice per group.

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Blocking Assay, Infection, Fluorescence, Microscopy

    NKG2D signaling mediates cytokine production in response to P. aeruginosa infection. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and cytokine levels in the whole lung were determined by an enzyme-linked immunosorbent assay at 24 h. Smaller amounts of IL-1β (A), TNF-α (B), and IFN-γ (C) were detected in the lungs of mice that were treated with the CX5 antibody. The data are means and standard errors of the means for five or six mice per group. An asterisk indicates that the value was significantly less than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: NKG2D signaling mediates cytokine production in response to P. aeruginosa infection. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and cytokine levels in the whole lung were determined by an enzyme-linked immunosorbent assay at 24 h. Smaller amounts of IL-1β (A), TNF-α (B), and IFN-γ (C) were detected in the lungs of mice that were treated with the CX5 antibody. The data are means and standard errors of the means for five or six mice per group. An asterisk indicates that the value was significantly less than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Infection, Blocking Assay, Enzyme-linked Immunosorbent Assay

    NKG2D signaling mediates nitric oxide (NO) production in response to P. aeruginosa infection. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and nitrite levels in the BAL were determined by the Griess reaction at 8 and 24 h postinfection. The data are means and standard errors of the means for five or six mice per group. The asterisk indicates that the value was significantly less than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: NKG2D signaling mediates nitric oxide (NO) production in response to P. aeruginosa infection. Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and nitrite levels in the BAL were determined by the Griess reaction at 8 and 24 h postinfection. The data are means and standard errors of the means for five or six mice per group. The asterisk indicates that the value was significantly less than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Infection, Blocking Assay

    Role of NKG2D in pulmonary inflammation and epithelial cell injury in response to P. aeruginosa infection. (A) Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and BAL cellularity was assessed at 24 h. No significant differences were observed in the total leukocytes recovered or the composition of the leukocytes in mice treated with the CX5 antibody. (B) The percentage of epithelial cells recovered from the BAL fluid at 24 h was reduced in P. aeruginosa-infected mice treated with the CX5 antibody compared to control-treated mice. The data are means and standard errors of the means for five mice per group. The asterisk indicates that the value was significantly less than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Journal:

    Article Title: The NKG2D-Activating Receptor Mediates Pulmonary Clearance of Pseudomonas aeruginosa

    doi: 10.1128/IAI.74.5.2578-2586.2006

    Figure Lengend Snippet: Role of NKG2D in pulmonary inflammation and epithelial cell injury in response to P. aeruginosa infection. (A) Mice were treated with the NKG2D receptor blocking antibody (100 μg of CX5) or control IgG prior to P. aeruginosa infection, and BAL cellularity was assessed at 24 h. No significant differences were observed in the total leukocytes recovered or the composition of the leukocytes in mice treated with the CX5 antibody. (B) The percentage of epithelial cells recovered from the BAL fluid at 24 h was reduced in P. aeruginosa-infected mice treated with the CX5 antibody compared to control-treated mice. The data are means and standard errors of the means for five mice per group. The asterisk indicates that the value was significantly less than the value for P. aeruginosa-infected, control, IgG-treated mice (P < 0.05).

    Article Snippet: Briefly, 12 to 16 h prior to infection, mice were inoculated intraperitoneally with either 100 μg rat anti-mouse NKG2D monoclonal antibody CX5 (eBioscience) or 100 μg control rat IgG.

    Techniques: Infection, Blocking Assay